Bvf Inc decreased its stake in Chemocentryx Inc (CCXI) by 78.1% based on its latest 2019Q1 regulatory filing with the SEC. Bvf Inc sold 5.22 million shares as the company’s stock rose 15.42% with the market. The hedge fund held 1.46 million shares of the health care company at the end of 2019Q1, valued at $20.34 million, down from 6.69 million at the end of the previous reported quarter. Bvf Inc who had been investing in Chemocentryx Inc for a number of months, seems to be less bullish one the $473.67 million market cap company. The stock decreased 1.45% or $0.12 during the last trading session, reaching $8.16. About 238,941 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 11.16% since July 20, 2018 and is uptrending. It has outperformed by 6.73% the S&P500. Some Historical CCXI News: 09/03/2018 ChemoCentryx 4Q EPS 80c; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M
Df Dent & Co Inc decreased its stake in Fastenal Co (FAST) by 8% based on its latest 2019Q1 regulatory filing with the SEC. Df Dent & Co Inc sold 192,537 shares as the company’s stock rose 2.08% with the market. The institutional investor held 2.22M shares of the building materials company at the end of 2019Q1, valued at $142.46 million, down from 2.41 million at the end of the previous reported quarter. Df Dent & Co Inc who had been investing in Fastenal Co for a number of months, seems to be less bullish one the $17.42B market cap company. The stock increased 0.23% or $0.07 during the last trading session, reaching $30.37. About 2.75 million shares traded. Fastenal Company (NASDAQ:FAST) has risen 24.22% since July 20, 2018 and is uptrending. It has outperformed by 19.79% the S&P500. Some Historical FAST News: 09/05/2018 – Fastenal Presenting at Macquarie Group Conference Tomorrow; 11/04/2018 – Fastenal Company to Host Investor Presentation; 11/04/2018 – Fastenal 1Q Operating Cash Flow $159.7M; 09/04/2018 – Fastenal Co expected to post earnings of 61 cents a share – Earnings Preview; 06/03/2018 – FASTENAL FEB. NET SALES UP 14.8%; 23/03/2018 – Fastenal Closes Below 50-Day Moving Average: Technicals; 01/05/2018 – Fastenal Company Recommends Rejection of Below-Market-Price Mini-Tender Offer by TRC Capital Corporation; 11/04/2018 – Fastenal 1Q-End Accounts Receivable Up 19.8%; 06/03/2018 FASTENAL FEB. DAILY SALES UP 14.8%; 11/04/2018 – Fastenal Sees 2018 Net Capital Expenditures About $149M
Investors sentiment increased to 1.44 in Q1 2019. Its up 0.51, from 0.93 in 2018Q4. It improved, as 12 investors sold CCXI shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. Alps Advsr accumulated 0.01% or 122,039 shares. National Bank Of America Corp De holds 0% or 92,817 shares in its portfolio. Parametric Limited Company holds 55,490 shares or 0% of its portfolio. Raymond James has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). California State Teachers Retirement invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Prudential Fincl reported 22,040 shares stake. Carmignac Gestion owns 0.32% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 1.97M shares. Art Ltd Liability Corp has 0.02% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Ameriprise Fin Inc holds 261,396 shares or 0% of its portfolio. Geode Capital Ltd Liability Co has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Walleye Trading Llc accumulated 14,800 shares or 0% of the stock. One Trading LP invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Ny State Common Retirement Fund holds 0% or 25,400 shares in its portfolio. Pub Employees Retirement Systems Of Ohio holds 99,284 shares. The New York-based Blackrock has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI).
Bvf Inc, which manages about $999.89M and $893.07M US Long portfolio, upped its stake in Alpine Immune Sciences Inc by 558,658 shares to 1.20 million shares, valued at $8.24M in 2019Q1, according to the filing. It also increased its holding in Corvus Pharmaceuticals Inc by 218,835 shares in the quarter, for a total of 2.11M shares, and has risen its stake in Five Prime Therapeutics Inc (NASDAQ:FPRX).
More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Nasdaq.com which released: “ChemoCentryx, Inc. (CCXI) in Focus: Stock Rises 9.6% – Tale of the Tape – NASDAQ” on October 17, 2014, also Globenewswire.com with their article: “ChemoCentryx Strengthens Senior Executive Team with the Appointment of William Fairey as Executive Vice President and Chief Operating Officer – GlobeNewswire” published on January 08, 2018, Seekingalpha.com published: “SCYNEXIS and ReWalk Robotics among healthcare gainers; Stellar Biotechnologies and ChemoCentryx among losers – Seeking Alpha” on June 05, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Finance.Yahoo.com and their article: “Hedge Funds Have Never Been More Bullish On ChemoCentryx Inc (CCXI) – Yahoo Finance” published on May 09, 2019 as well as Seekingalpha.com‘s news article titled: “InflaRx Tanks 91.79% As IFX-1 Phase II Trial Flops, Provides Bargain Buy For Competitor ChemoCentryx – Seeking Alpha” with publication date: June 08, 2019.
Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on August, 8. They expect $-0.21 EPS, down 50.00% or $0.07 from last year’s $-0.14 per share. After $-0.23 actual EPS reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts -8.70% EPS growth.
Since January 22, 2019, it had 0 insider purchases, and 1 sale for $457,747 activity.
Since January 29, 2019, it had 0 insider purchases, and 4 sales for $3.57 million activity. The insider DOLAN MICHAEL JOHN sold $150,000. Another trade for 5,000 shares valued at $302,550 was sold by LUNDQUIST NICHOLAS J. Hein LeLand J also sold $2.49 million worth of Fastenal Company (NASDAQ:FAST) shares.
Investors sentiment decreased to 0.88 in Q1 2019. Its down 0.15, from 1.03 in 2018Q4. It turned negative, as 38 investors sold FAST shares while 229 reduced holdings. 76 funds opened positions while 159 raised stakes. 234.08 million shares or 1.90% less from 238.60 million shares in 2018Q4 were reported. Court Place Advsrs Lc accumulated 12,145 shares or 0.32% of the stock. Meeder Asset Mngmt holds 0.01% or 1,274 shares in its portfolio. Hightower Advisors Ltd Liability Corporation holds 0.04% or 90,679 shares. Hbk Sorce Advisory Ltd Limited Liability Company holds 0.02% or 3,684 shares in its portfolio. Trust Of Virginia Va has invested 0.98% in Fastenal Company (NASDAQ:FAST). Kornitzer Cap Ks stated it has 0.01% in Fastenal Company (NASDAQ:FAST). Essex Investment Co Llc stated it has 7,500 shares. Moreover, Parkside Fin Savings Bank & Tru has 0.06% invested in Fastenal Company (NASDAQ:FAST). Robeco Institutional Asset Bv invested in 0.07% or 313,553 shares. Greenleaf Trust reported 25,482 shares. 994,109 are owned by Amundi Pioneer Asset Management. Nuwave Mgmt Ltd Llc invested 0.03% of its portfolio in Fastenal Company (NASDAQ:FAST). Morgan Stanley holds 0.02% of its portfolio in Fastenal Company (NASDAQ:FAST) for 1.12M shares. Reilly Fin Advsrs Lc reported 759 shares stake. Harvey Inv Co Ltd Liability Co holds 3.95% of its portfolio in Fastenal Company (NASDAQ:FAST) for 357,482 shares.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.